Evidence map›Paper›PMID 32521651›Full record

ArticleTropical medicine and infectious disease2020

Performance of an Automated Zika IgG Immunoassay in the Detection of Zika IgG Specific Antibodies-A Validation Approach in Samples from Prevalence Areas and Non-Endemic Countries.

Tina Laengin, Stephanie Augenstein, Elke Stadlbauer, Heike Girgnhuber, Mario Gloeck, Alexander Riedel

Open access · goldAbstract read
In one paragraph

Article in Tropical medicine and infectious disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tina LaenginCentralised and Point of Care Solutions, Roche Diagnostics GmbH, D‑82377 Penzberg, Germany.
Stephanie AugensteinCentralised and Point of Care Solutions, Roche Diagnostics GmbH, D‑82377 Penzberg, Germany.
Elke StadlbauerCentralised and Point of Care Solutions, Roche Diagnostics GmbH, D‑82377 Penzberg, Germany.
Heike GirgnhuberCentralised and Point of Care Solutions, Roche Diagnostics GmbH, D‑82377 Penzberg, Germany.
Mario GloeckCentralised and Point of Care Solutions, Roche Diagnostics GmbH, D‑82377 Penzberg, Germany.
Alexander RiedelCentralised and Point of Care Solutions, Roche Diagnostics GmbH, D‑82377 Penzberg, Germany.
Roche Pharma AG (Germany) · DE

Funding

Roche Diagnostics GmbH NA
6 · The paper itself

Abstract

The diagnosis of Zika virus infection is complicated and includes testing for nucleic acids and IgM and IgG antibodies, depending on the stage of infection. Zika IgG is an important marker of infection after the acute stage; however, IgG assays can lack specificity due to the similarities between Zika and other flaviviruses. In this study, the diagnostic sensitivity and specificity of the Elecsys

Identifiers

PMID32521651
PMCPMC7344800
OpenAlexW3034162834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.